Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project.

Details

Ressource 1Download: s12879-016-1968-2.pdf (562.65 [Ko])
State: Public
Version: Final published version
Serval ID
serval:BIB_2E1EBE8BEC65
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project.
Journal
BMC infectious diseases
Author(s)
Ngo-Giang-Huong N., Wittkop L., Judd A., Reiss P., Goetghebuer T., Duiculescu D., Noguera-Julian A., Marczynska M., Giacquinto C., Ene L., Ramos J.T., Cellerai C., Klimkait T., Brichard B., Valerius N., Sabin C., Teira R., Obel N., Stephan C., de Wit S., Thorne C., Gibb D., Schwimmer C., Campbell M.A., Pillay D., Lallemant M.
Working group(s)
EuroCoord-CHAIN-EPPICC joint project study group
ISSN
1471-2334 (Electronic)
ISSN-L
1471-2334
Publication state
Published
Issued date
08/11/2016
Peer-reviewed
Oui
Volume
16
Number
1
Pages
654
Language
english
Notes
Publication types: Journal Article ; Observational Study
Publication Status: epublish
Abstract
Few studies have evaluated the impact of pre-treatment drug resistance (PDR) on response to combination antiretroviral treatment (cART) in children. The objective of this joint EuroCoord-CHAIN-EPPICC/PENTA project was to assess the prevalence of PDR mutations and their association with virological outcome in the first year of cART in children.
HIV-infected children <18 years initiating cART between 1998 and 2008 were included if having at least one genotypic resistance test prior to cART initiation. We used the World Health Organization 2009 resistance mutation list and Stanford algorithm to infer resistance to prescribed drugs. Time to virological failure (VF) was defined as the first of two consecutive HIV-RNA > 500 copies/mL after 6 months cART and was assessed by Cox proportional hazards models. All models were adjusted for baseline demographic, clinical, immunology and virology characteristics and calendar period of cART start and initial cART regimen.
Of 476 children, 88 % were vertically infected. At cART initiation, median (interquartile range) age was 6.6 years (2.1-10.1), CD4 cell count 297 cells/mm(3) (98-639), and HIV-RNA 5.2 log10copies/mL (4.7-5.7). Of 37 children (7.8 %, 95 % confidence interval (CI), 5.5-10.6) harboring a virus with ≥1 PDR mutations, 30 children had a virus resistant to ≥1 of the prescribed drugs. Overall, the cumulative Kaplan-Meier estimate for virological failure was 19.8 % (95 %CI, 16.4-23.9). Cumulative risk for VF tended to be higher among children harboring a virus with PDR and resistant to ≥1 drug prescribed than among those receiving fully active cART: 32.1 % (17.2-54.8) versus 19.4 % (15.9-23.6) (P = 0.095). In multivariable analysis, age was associated with a higher risk of VF with a 12 % reduced risk per additional year (HR 0.88; 95 %CI, 0.82-0.95; P < 0.001).
PDR was not significantly associated with a higher risk of VF in children in the first year of cART. The risk of VF decreased by 12 % per additional year at treatment initiation which may be due to fading of PDR mutations over time. Lack of appropriate formulations, in particular for the younger age group, may be an important determinant of virological failure.

Keywords
Adolescent, Anti-HIV Agents/therapeutic use, CD4 Lymphocyte Count, Child, Child, Preschool, Drug Resistance, Viral/drug effects, Drug Resistance, Viral/genetics, Drug Therapy, Combination, Female, HIV Infections/drug therapy, HIV Infections/mortality, HIV Infections/virology, HIV-1/drug effects, Humans, Infant, Kaplan-Meier Estimate, Male, Mutation, Reverse Transcriptase Inhibitors/therapeutic use, Viral Load/drug effects, Children, First-line combination antiretroviral therapy, HIV, Pre-treatment drug resistance mutations, Virological failure
Pubmed
Web of science
Open Access
Yes
Create date
30/11/2016 20:46
Last modification date
20/08/2019 13:12
Usage data